ICLUSIG (ponatinib) offers convenient dosing in a single oral tablet1

Available in 45 mg, 30 mg, 15 mg, and 10 mg dosage strengths1

ICLUSIG is a single tablet taken orally once daily1

  • Can be taken with or without food
  • Tablets should be swallowed whole. Do not crush, break, cut, or chew tablets
  • If a dose is missed, take the next dose at the regularly scheduled time the next day
ICLUSIG is available in 45mg, 30mg, 15mg, and 10mg tablets.

ICLUSIG is available in multiple dosage strengths. Each dosage strength is available as a single oral tablet.1

Guidance for dose modification in CP-, AP-, BP-CML

ICLUSIG (ponatinib) dose modifications
Recommended Dose Modifications for ICLUSIG for Adverse Reactions1
Recommended dosing modifications for specific adverse reactions.

Based on CTCAE v5.0: Grade 1 mild, Grade 2 moderate, Grade 3 severe, Grade 4 life-threatening

ICLUSIG (ponatinib) dose reductions
Recommended Dose Reductions for ICLUSIG for Adverse Reactions1
Recommended dose reductions for patients with CP-CML, AP-CML, and BP-CML.
ICLUSIG (ponatinib) dosage with strong CYP3A inhibitors
Recommended ICLUSIG Dosage for Co-administration of Strong CYP3A Inhibitors1
Dose reduction for patients with a strong CYP3A Inhibitor.

ICLUSIG (ponatinib) dosage for patients with hepatic impairment1

Reduce the starting doses of ICLUSIG from 45 mg orally once daily to 30 mg orally once daily in patients with pre-existing hepatic impairment (Child-Pugh A, B, or C).

Dosing strategy in AP-CML, BP-CML, and Ph+ ALL1

  • Optimal dose of ICLUSIG has not been identified in AP- and BP-CML
  • Recommended starting dosage is 45 mg orally once daily
  • Consider reducing dosage for patients with AP-CML who have achieved a major cytogenetic response
  • Continue treatment with ICLUSIG until loss of response or unacceptable toxicity
  • Consider discontinuing ICLUSIG if response has not occurred by 3 months

Learn about a response-based dosing approach with ICLUSIG

Discover which patients are appropriate for ICLUSIG

ALT=alanine transaminase; ANC=absolute neutrophil count; AOE=arterial occlusive events; AP-CML=accelerated-phase chronic myeloid leukemia; AST=aspartate aminotransferase; BCR-ABL1IS=BCR-ABL1 international scale; BP-CML=blast-phase chronic myeloid leukemia; CP-CML=chronic-phase chronic myeloid leukemia; CTCAE=Common Terminology Criteria for Adverse Events; TKI=tyrosine kinase inhibitor; ULN=upper limit of normal.